Exposure to pseudoephedrine during pregnancy and major congenital malformations: Findings from a large population‐based cohort of pregnancies
British Journal of Clinical Pharmacology · 2025-06 · 91 (6) · 1834-1841
DOI: 10.1002/bcp.70001 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 16.02.2025. Verfasst von Saar Dor und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Biostatistics, and Community Health Sciences, School of Public Health, Ben-Gurion University of the Negev, Beer-Sheva, Is…. Hauptthemen laut MEDLINE: Abnormalities, Drug-Induced, Pseudoephedrine, Tocolytic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
The aim of this study was to assess the risk of major congenital malformations following first‐trimester pseudoephedrine (PSE) exposure.
Methods
A population‐based observational cohort study was conducted on pregnancies of women aged 15–49 years, insured by Clalit Health Services in southern Israel, who gave birth or had elective pregnancy terminations due to suspected fetal malformation at Soroka Medical Center (1999–2017). The study focused on Clarinase, a drug that contains a high dose of PSE (120 mg) and 5 mg of loratadine. Multivariable negative binomial regression models were used to evaluate the risk for major congenital malformations, adjusting for potential confounders.
Results
Of 251 543 pregnancies, 313 (0.12%) were exposed to high‐dose PSE in the first trimester. PSE exposure was not associated with major congenital malformations overall (adjusted relative risk [aRR] = 0.90, 95% confidence interval [CI] 0.558–1.45; P = 0.66) or by organ system (cardiovascular: aRR = 0.938, 95% CI 0.499–1.762; central nervous system: aRR = 0.618, 95% CI 0.086–4.451; musculoskeletal: aRR = 1.800, 95% CI 0.801–4.042; gastrointestinal: aRR = 1.013, 95% CI 0.142–7.241; genitourinary: aRR = 0.704, 95% CI 0.225–2.204).
Conclusions
First‐trimester PSE exposure was not an independent risk factor for major congenital malformations, either overall or by organ system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Biostatistics, and Community Health Sciences, School of Public Health, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
- Obstetrics and Gynecology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
- Adelson School of Medicine, Ariel University, Ariel, Israel.
- Department of Social Services, Soroka University Medical Center, Beer Sheva, Israel.
- Department of Pediatrics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
- Clalit Health Services, Southern District, Beer-Sheva, Israel.
ORCID-Profile: Saar Dor, Yael Levi, Sharon Daniel
Zitieren
APA
Dor, S., Michael, T., Levi, Y., Pariente, G., Lunenfeld, E., Levy, A., Birenstock-Cohen, S., & Daniel, S. (2025). Exposure to pseudoephedrine during pregnancy and major congenital malformations: Findings from a large population‐based cohort of pregnancies. British Journal of Clinical Pharmacology, 91(6), 1834-1841. https://doi.org/10.1002/bcp.70001
Vancouver
Dor S, Michael T, Levi Y, Pariente G, Lunenfeld E, Levy A, et al. Exposure to pseudoephedrine during pregnancy and major congenital malformations: Findings from a large population‐based cohort of pregnancies. British Journal of Clinical Pharmacology. 2025;91(6):1834-1841. doi:10.1002/bcp.70001
BibTeX
@article{Dor2025,
author = {Dor, Saar and Michael, Tal and Levi, Yael and Pariente, Gali and Lunenfeld, Eitan and Levy, Amalia and Birenstock-Cohen, Shira and Daniel, Sharon},
title = {Exposure to pseudoephedrine during pregnancy and major congenital malformations: Findings from a large population‐based cohort of pregnancies},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
volume = {91},
number = {6},
pages = {1834--1841},
doi = {10.1002/bcp.70001}
}
EUVIMED